본문으로 건너뛰기
← 뒤로

Oligometastatic pancreatic cancer: current state of management and emerging therapies.

The oncologist 2025 Vol.30(6)

Khomiak A, Balmaceda NB, Ghaffar SA, Lieu CH, Del Chiaro M, Messersmith WA, Lentz RW

📝 환자 설명용 한 줄

Oligometastatic pancreatic cancer is a distinct clinical entity with limited metastatic burden.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Khomiak A, Balmaceda NB, et al. (2025). Oligometastatic pancreatic cancer: current state of management and emerging therapies.. The oncologist, 30(6). https://doi.org/10.1093/oncolo/oyaf154
MLA Khomiak A, et al.. "Oligometastatic pancreatic cancer: current state of management and emerging therapies.." The oncologist, vol. 30, no. 6, 2025.
PMID 40536269

Abstract

Oligometastatic pancreatic cancer is a distinct clinical entity with limited metastatic burden. This unique subset of patients harbor a favorable tumor biology and potentially better prognosis compared to widespread metastatic disease. This review explores definitions of oligometastatic pancreatic cancer and the current state of management, including systemic therapy, surgery, and locoregional techniques. While there are few randomized clinical trials directing the management of oligometastatic pancreatic cancer, we provide insights into the treatment challenges, evolving therapeutic approaches, and future directions for this unique subset of patients.

MeSH Terms

Humans; Pancreatic Neoplasms; Neoplasm Metastasis

같은 제1저자의 인용 많은 논문 (2)